Enteris Biopharma Inc., of Boonton, N.J., said its development partner, Cara Therapeutics Inc., of Shelton, Conn., dosed the first subjects in a further phase Ia/Ib trial of a tablet formulation of its peripherally selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain.